Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TENPA in Advanced Solid Tumors
NCT02979392Phase 1Terminated
- Start
- May 2016
- Primary completion
- Jul 2019
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of TENPA in solid tumor (advanced stage). Primary endpoint: Dose Limiting Toxicity at 3 weeks. Started May 2016; status: terminated.
02
Drugs
TENPA
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02979392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02979392.